

4D pharma plc

02:28 06 Jul 2020

4D pharma PLC treats first patients in the second stage of its phase I/II cancer trial

4D pharma plc (LON:DDDD) has said the crucial next stage of a cancer clinical study is underway with four new sites added in the US to accelerate patient recruitment.

Up to 30 people per tumour type will participate in Part B of the company's phase I/II trial to assess its live biotherapeutic, MRx0518, in combination with immune checkpoint inhibitor Keytruda.

The assessment will look for a meaningful clinical impact on cancer patients that have become resistant to this type of therapy.

Researchers are looking for a complete or partial response or stable disease for six months or longer.

Safety already assessed

Safety and tolerability will also be evaluated, although Part A of the study has already indicated there were no serious adverse events; no treatment-related drug discontinuations; and no increase of immune-related adverse events

Of the 12 people enrolled in Part A, five are still taking the combination therapy. They include two patients with a partial response to the regimen, one patient with ongoing stable disease for over six months, and two with ongoing stable disease for less than six months.

Working in the emerging area of the human microbiome (the bacteria that reside mainly in the gut), 4D has developed Live Biotherapeutics — products that contain live organisms such as human commensal bacteria.

The approach focuses on single strains to assess specific mechanisms of action targeting a defined disease pathway. Even variations between different strains of bacteria of the same species are assessed and exploited.

The work on Keytruda addresses the fact that sadly, over time, the effect of this class of drug can wane.

Re-engaging the immune system

So, MRx0518 is being trialled to assess its potential to work synergistically with Keytruda to re-engage the immune system.

"Part A of our trial demonstrated that 4D pharma's candidate MRx0518 may provide benefit to this group of patients," 4d chief executive Duncan Peyton said in a statement.

"Commencing Part B of the study and opening new sites in the US to accelerate recruitment will allow us to build quickly on the positive results of Part A. Continued positive results will support MRx0518 as a much-needed novel therapeutic for patients who currently have no alternative treatment options.

Price: 116

Market Cap: £152.42 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: DDDD

Listing: LSE

52 week	High	Low
	183	23.5

Sector: Pharma & Biotech

Website: www.4dpharmapl.com

Company Synopsis:

4D are pioneers in harnessing bacteria as a revolutionary new class of medicines - called live biotherapeutics.

action@proactiveinvestors.com

"This is another important step towards our aim to have the first approved Live Biotherapeutic in an oncology setting," he concluded.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).